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Background: Viral infections of the respiratory tract represent a major global health concern. Co-infection with
bacteria may contribute to severe disease and increased mortality in patients. Nevertheless, viral-bacterial co-
infection patterns and their clinical outcomes have not been well characterized to date. This study aimed to eval-
uate the clinical features and outcomes of patients with viral-bacterial respiratory tract co-infections.
Methods: We included 19,361 patients with respiratory infection due to respiratory viruses [influenza A and B,
respiratory syncytial virus (RSV), parainfluenza] and/or bacteria in four tertiary hospitals in Hong Kong from 2013
to 2017 using a large territory-wide healthcare database. All microbiological tests were conducted within 48 h of
hospital admission. Four etiological groups were included: (1) viral infection alone; (2) bacterial infection alone; (3)
laboratory-confirmed viral-bacterial co-infection and (4) clinically suspected viral-bacterial co-infection who were
tested positive for respiratory virus and negative for bacteria but had received at least four days of antibiotics. Clini-
cal features and outcomes were recorded for laboratory-confirmed viral-bacterial co-infection patients compared
to other three groups as control. The primary outcome was 30-day mortality. Secondary outcomes were intensive
care unit (ICU) admission and length of hospital stay. Propensity scorematching estimated by binary logistic regres-
sion was used to adjust for the potential bias that may affect the association between outcomes and covariates.
Findings: Among 15,906 patients with respiratory viral infection, there were 8451 (53.1%) clinically suspected
and 1,087 (6.8%) laboratory-confirmed viral-bacterial co-infection. Among all the bacterial species, Haemophilus
influenzae (226/1,087, 20.8%), Pseudomonas aeruginosa (180/1087, 16.6%) and Streptococcus pneumoniae (123/
1087, 11.3%) were the three most common bacterial pathogens in the laboratory-confirmed co-infection group.
Respiratory viruses co-infected with non-pneumococcal streptococci or methicillin-resistant Staphylococcus
aureus was associated with the highest death rate [9/30 (30%) and 13/48 (27.1%), respectively] in this cohort.
Compared with other infection groups, patients with laboratory-confirmed co-infection had higher ICU admis-
sion rate (p < 0.001) and mortality rate at 30 days (p = 0.028), and these results persisted after adjustment for
potential confounders using propensity score matching. Furthermore, patients with laboratory-confirmed co-
infection had significantly higher mortality compared to patients with bacterial infection alone.Keywords:
Respiratory
viral-bacterial co-infection
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for bacterial co-infection and early antibiotic treatment may be required to improve outcomes in patients
with respiratory viral infection.
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ation.1. Introduction
Community-acquired respiratory infection is one of the major
causes of morbidity and mortality, especially among the elderlypopulation [1,2]. The prevalence of contributory pathogens have,
however, changed over time [3]. Influenza pandemics have demon-
strated the harmful effects of viral-bacterial co-infection [4,5]. Sec-
ondary bacterial infection was the predominant cause of death
among patients infected with the Spanish flu in 1918 [6]. During the
pre-antibiotic era, almost all patients who died in the Spanish flu
pandemic had at least one bacterial pathogen isolated from the respi-
ratory tract. In the subsequent 1957 Asian influenza and H1N1 pan-
demics, bacterial pathogens were commonly found in patients who
died, albeit less consistently (2550%) [79]. In the latest 2009 H1N1
pandemic, only 17.5% of patients with viral pneumonia had bacterial
co-infection [10]. In addition, respiratory syncytial virus (RSV) that
commonly infects children and the elderly [11], is associated with
Streptococcus pneumoniae, Haemophilus influenzae,
and Staphylococcus aureus [1214]. Temporal changes in vaccination
[15], population structure [16,17], selection pressure from antibiotics
[18,19], and availability of highly sensitive detection method with
viral polymerase chain reaction (PCR) [20], may account for the
changing pattern.
Numerous studies have demonstrated the detrimental interac-
tions between viruses and bacteria that commonly infect the
human respiratory tract. Such interactions could produce impaired
mucociliary clearance, enhanced bacterial binding, changes in
respiratory tract receptor expression, dysregulated immune
response and decreased bacterial clearance [2128]. There is also
evidence that bacterial infection or altered microbiome in the
respiratory tract may enhance subsequent viral infection [29]. The
complex pathogen-host interactions in patients with viral-bacte-
rial co-infection may therefore lead to serious adverse outcomes
[16,30,31]. In this respect, a meta-analysis of 31 studies showed
an increase in mortality among patients with pneumonia due to
viral-bacterial co-infection [32]. Another study focusing on
patients admitted to the intensive care unit (ICU) produced similar
results [31]. However, recent epidemiological data failed to dem-
onstrate higher mortality of viral-bacterial co-infection [16,33].
Furthermore, apart from influenza and RSV, interactions between
other respiratory viruses and bacteria have not been characterized
due to the limited sample size. Using a large database, we ana-
lyzed the 30-day mortality, intensive care unit (ICU) admission
and duration of hospital stay in adult patients hospitalized for viral
and/or bacterial respiratory infection. We hypothesized that
patients with laboratory-confirmed viral-bacterial co-infection
were associated with worse outcome compared with those having
bacterial or viral infection alone.
2. Methods
2.1. Study design
In this analysis, we included consecutive adult (>18 years)
patients hospitalized for respiratory infection, who had both viral
and bacterial respiratory sampling, between 1 January 2013 and 31
December 2017 from four major hospitals in Hong Kong. These
patients were identified through the Clinical Data Analysis and
Y. Liu et al. / EClinicalMedicine 37 (2021) 100955 3Report System (CDARS), which is a computerized clinical database of
the Hospital Authority of Hong Kong. As the sole independent public
health provider, the Hospital Authority has built a public healthcare
infrastructure that covers over 90% acute in-patient services in Hong
Kong [34]. Patients were also excluded if they were managed as out-
patient, had incomplete clinical records, or had multiple viral or bac-
terial infections. After excluding these cases, we extracted clinical
data including baseline demographics, comorbidities using the Inter-
national Classification of Diseases, Ninth Revision (ICD9) diagnosis
codes (Table S1), medication used, ICU admission, and 30-day mor-
tality. Ethics approval was obtained from the Chinese University of
Hong Kong with wavier of informed consent (CREC Ref. No.:
2018.358).2.2. Laboratory confirmed infections and treatment
Respiratory microbiological samples were tested for viral and bac-
terial pathogens. For viral tests, samples collected from nasal flock
swab, nasopharyngeal aspirate, tracheal aspirate, bronchial aspirate
and/or bronchoalveolar lavage were analyzed with PCR for influenza
A and B, RSV, and parainfluenza types 1, 2, 3, and 4. Patients who
were tested positive for adenovirus, enterovirus, rhinovirus, or
human metapneumovirus were not included in the study because
test availability was inconsistent during the study period. For bacte-
rial tests, samples from sputum, tracheal aspirates, bronchoalveolar
lavage, bronchial washing, pleural biopsy and/or blood cultures were
sent for bacterial or mycobacterium cultures (Table S2). Matrix-
assisted laser desorption/ionization-time of flight mass spectrometry
was used for bacteria identification. All included cases had both viral
and bacterial tests done. All samples were collected within 48 h of hos-
pital admission and have at least one upper respiratory infection symp-
toms. We excluded cases with multiple organisms in the viral tests or
bacterial cultures to avoid cases with commensal contamination.
During the study period, the clinical management protocols were
consistent among all hospitals. Antibiotics were generally prescribed
upon hospital admission and usually stopped < 4 days if the patient
did not respond clinically or bacterial cultures were found negative.
The duration of antibiotics was chosen as the threshold to indicate
non-bacterial infection according to the recommended use ofFig. 1. Flowchart of research methodology, screenig, eligibiliantibacterial in adult sepsis event defined by the Centers for Disease
Control and Prevention [35]. Patients who had antibiotics but died
within four days of admission were considered to have been treated
for bacterial infection clinically.2.3. Group categorization and outcomes
Four groups of patients were defined in this study: (1) Viral infec-
tion alone group included patients who were tested positive for any
respiratory virus by PCR but negative for bacteria by bacterial or
mycobacterial culture, and received antibiotics for < 4 days; (2) Bac-
terial infection alone group included patients who had positive cul-
ture for any respiratory bacterial or mycobacterial species but
negative for respiratory virus by PCR, and received a course of antibi-
otics  4 days; (3) Laboratory-confirmed viral-bacterial co-infection
group included patients with positive laboratory confirmation of viral
PCR test and bacterial/mycobacterial culture, and received a course of
antibiotics  4 days; (4) Clinically suspected viral-bacterial co-infec-
tion group included patients with a positive viral PCR test, negative
bacterial culture and received a course of antibiotics  4 days (Fig. 1).
The primary outcome was all-cause mortality within 30 days of
hospital admission. Secondary outcomes were the proportions of
patients requiring ICU admission and number of days of hospital
length of stay.2.4. Statistics
Baseline characteristics were compared among four groups using
analysis of variance for continuous variables (including age, length of
hospital stay and the laboratory data), post-hoc analysis was adjusted
by Tukey’s test. For categorical data (sex and comorbidities), we used
chi square test. Since there were variations in the baseline character-
istics among groups, we adjusted outcome comparisons using pro-
pensity analysis. Three pairs of between group comparisons were
made. In each pair, the laboratory-confirmed viral-bacterial co-infec-
tion group was compared with one of the three reference groups, i.e.
either viral infection alone, bacterial infection alone, or clinically sus-
pected viral-bacterial co-infection. Propensity score was calculated as
the probability of laboratory-confirmed viral-bacterial co-infectionty and enrollment of patients with respiratory infection.
4 Y. Liu et al. / EClinicalMedicine 37 (2021) 100955versus the respective reference group, adjusted by sex, age, and the
baseline risk factors in the Charlson’s comorbidity index using binary
logistic regression [36]. One-to-one propensity matching was per-
formed with the matchit package in R using the nearest neighbor
approach within a caliper distance (i.e. standard deviation of logit of
the propensity score) of 0.2 [37,38]. Before propensity matching, sev-
eral baseline variables showed standardized mean difference >0.1
between the laboratory-confirmed viral-bacterial co-infection group
and the respective reference group, including hemiplegia or paraple-
gia, peripheral vascular disease, rheumatic disease, liver disease and
acquired immunodeficiency syndrome (Tables S35). After match-
ing, standardized mean difference between groups was reduced to
<0.1 in all baseline variables. Cox proportional hazard model was
used to calculate the hazard ratio of 30-day mortality, with robust
variance estimator to account for the clustering within matched pairs
[39]. KaplanMeier plot was used to demonstrate the difference in
survival probabilities between groups after propensity score match-
ing. Subgroup analysis was performed for patients requiring ICU
admission. Relative risk was calculated for the association between
co-infection and ICU admission outcome. Crude 30-day mortality and
prevalence of different viral-bacterial co-infection combinations
were calculated for selected combinations with an incidence  20Table 1
Baseline characteristics between patients with different types of infection.
Viral infection
alone N = 6368
Bacterial infection
alone N = 3455
Age, Mean (SD)
68.7 (20.1) 69.2 (17.9)
Age group (%)
<65 2252 (35.4) 1208(35.0)
6574 945 (14.8) 665 (19.2)
7584 1615 (25.4) 843 (24.4)
85 1556 (24.4) 739 (21.4)
Sex (%)
Female 3358 (52.7) 1502 (43.5)
Comorbidities (%) 4019 (63.1) 2026 (58.6)
Myocardial infarction 477 (7.5) 154 (4.5)
Congestive heart failure 858 (13.5) 287 (8.3)
Peripheral vascular disease 153 (2.4) 54 (1.6)
Cerebrovascular disease 1032 (16.2) 274 (7.9)
Chronic pulmonary disease 1220 (19.2) 662 (19.2)
Diabetes mellitus 1196 (18.8) 574 (16.6)
Rheumatic disease 95 (1.5) 46 (1.3)
Peptic ulcer disease 278 (4.4) 69 (2.0)
Hemiplegia/paraplegia 184 (2.9) 30 (0.9)
Dementia 418 (6.6) 116 (3.4)
Renal disease 531 (8.3) 225 (6.5)
Malignancy 651 (10.2) 397 (11.5)
Liver disease 396 (6.2) 191 (5.5)
Metastatic solid tumor 175 (2.7) 156 (4.5)
Acquired immunodeficiency syndrome 7 (0.1) 11 (0.3)
Laboratory result
Neutrophil
Mean (SD) 6.6 (4.0) 9.9 (5.5)
Missing (%) 256 (4.0) 97 (2.8)
Lymphocyte
Mean (SD) 1.0 (1.8) 1.1 (2.7)
Missing (%) 256 (4.0) 97 (2.8)
Neutrophil to lymphocyte ratio
Mean (SD) 9.8 ()9.7 14.7 (16.2)
Missing (%) 256 (4.0) 97 (2.8)
Platelet
Mean (SD) 191.5 (78.6) 227.0 (101.8)
Missing (%) 164 (2.6) 49(1.4)
C-reactive protein
Mean (SD) 5.8 (6.3) 10.9 (9.8)
Missing (%) 2405 (37.8) 842 (24.4)
Hospital length of stay, Mean (SD) 7.1 (18.3) 7.3 (9.3)
SD = standard deviations.
p values are for analysis of variance or chi square test*.cases. Multiple testing was adjusted by Bonferroni correction. All sta-
tistical analysis was conducted in R version 4.0.0 (R Project for Statis-
tical Computing). Nominal p-value less than 0.05 was considered as
statistically significant.
2.5. Role of funding
The funders had no role in study design, data collection and analy-
sis, decision to publish, or preparation of the manuscript.
3. Results
3.1. Study population and baseline characteristics
We included 19,361 adult hospitalized patients (mean age 69
years (SD: 19)) with positive PCR tests for respiratory virus and/or
bacteriological culture over the 5-year period. A total of 6368 patients
had viral infection alone (32.9%), 3455 (17.8%) had bacterial infection
alone, 1087 (5.6%) had laboratory-confirmed viral-bacterial co-infec-
tion, and 8451 (43.6%) had clinically suspected viral-bacterial co-
infection (Fig. 1). Table 1 shows significant differences in the distri-








70.9 (17.0) 69.1 (18.8)
<0.001*
330 (30.4) 3028 (35.8)
215 (19.8) 1358 (16.1)
306 (28.2) 2132 (25.2)
236 (21.7) 1933 (22.9)
<0.001*
511 (47.0) 4300 (50.9)
741 (68.2) 5155 (61.0) <0.001*
72 (6.6) 486 (5.8) <0.001*
128 (11.8) 983 (11.6) <0.001*
25 (2.3) 139 (1.6) 0.002*
144 (13.2) 1250 (14.8) <0.001*
295 (27.1) 1478 (17.5) <0.001*
181 (16.7) 1496 (17.7) 0.036*
27 (2.5) 144 (1.7) 0.047*
51 (4.7) 308 (3.6) <0.001*
18 (1.7) 248 (2.9) <0.001*
61 (5.6) 541 (6.4) <0.001*
94 (8.6) 608 (7.2) 0.002*
135 (12.4) 944 (11.2) 0.064*
73 (6.7) 519 (6.1) 0.411*
29 (2.7) 209 (2.5) <0.001*
2 (0.2) 14 (0.2) 0.131*
<0.001
7.9 (4.9) 6.4 (3.9)
35 (3.2) 276 (3.3)
0.057
0.9 (0.7) 1.0 (3.4)
35 (3.2) 276 (3.3)
<0.001
12.6 (14.8) 9.6 (10.8)
35 (3.2) 276 (3.3)
<0.001
200.7 (92.2) 187.1 (76.7)
23 (2.1) 157 (1.9)
10.1 (8.9) 5.9 (6.3) <0.001
365 (33.6) 3136 (37.1)
9.3 (22.9) 5.5 (10.9) <0.001
Table 2
Outcomes of patients with different types of infection.




Risk of the coinfection
group [95% CI]
p-value Reference group Laboratory-confirmed
viral-bacterial
coinfection group





versus viral infection alone
N = 6368 N = 1087 N = 1083 N = 1083
30-day mortality N (%) 332 (5.2%) 118 (10.9%) HR =2.2 [1.8, 2.7] <0.001 47 (4.3%) 117 (10.8%) HR =2.6 [1.9, 3.7] <0.001
ICU admission N (%) 207 (3.3%) 103 (9.5%) RR = 2.9 [2.3, 3.7] <0.001 35 (3.2%) 102 (9.42%) RR =2.9 [2.3, 3.6] <0.001
Laboratory-confirmed viral-bacterial co-infection
versus bacterial infection alone
N = 3455 N = 1087 N = 1083 N = 1083
30-day mortality N (%) 310 (9.0%) 118 (10.9%) HR =1.3
[1.01, 1.5] 0.114 79 (7.3%) 116 (10.7%) HR =1.4 [1.1, 1.9] 0.028
ICU admission N (%) 196 (5.7%) 103 (9.5%) RR= 1.8
[1.3, 2.1] <0.001 44 (4.1%) 103 (9.5%) RR =1.6 [1.2, 2.1] <0.001
Laboratory-confirmed viral-bacterial co-infection
versus clinically suspected viral-bacterial co-
infection
N = 8451 N = 1087 N = 1086 N = 1086
30-day mortality N (%) 400 (4.7%) 118 (10.9%) HR =2.4
[1.9, 2.9] <0.001 53 (4.9%) 118 (10.9%) HR =2.3 [1.7, 3.2] <0.001
ICU admission N (%) 254 (3.0%) 103 (9.5%) RR =3.15




* The propensity score matching was performed using laboratory-confirmed viral-bacterial co-infection versus respective reference groups (either viral infection alone, bacterial infection alone, or clinical suspected viral-bacterial co-infec-








Fig. 2. KaplanMeier curves for the 30-day mortality of the four types of infection groups. The figure presents the trend of the 30-day survival rate in each group. The log-rank test
for reference groups versus laboratory-confirmed co-infection group was done and shown in the figure. Data after propensity score matching were used for the comparison, and
the matching result of the laboratory-confirmed viral-bacterial co-infection group versus bacterial infection alone group was used as the co-infection group in this plot.
6 Y. Liu et al. / EClinicalMedicine 37 (2021) 100955with laboratory-confirmed viral-bacterial co-infection and bacterial
infection alone had higher neutrophil count, neutrophil-to-lympho-
cyte ratio, C-reactive protein, and platelet count than viral infection
alone and clinical suspected viral-bacterial co-infection (Table 1; p
values of the post-hoc analysis ranged from <0.001 to 0.005).
3.2. Clinical outcomes of different infection groups
Overall, 30-day mortality in the entire cohort was 6.0% (1160/
19,361) with 3.9% (760/19,361) of patients admitted to ICU. Propen-
sity matching for the baseline variables minimized the difference in
covariates among different infection groups (Tables S35). After pro-
pensity matching, laboratory-confirmed viral-bacterial co-infection
was significantly higher in 30-day mortality and ICU admission com-
pared with reference group (either viral infection alone, bacterial
infection alone, or clinical suspected viral-bacterial co-infection
group) (Table 2, Fig. 2). A subgroup analysis among the propensity
matched patients requiring ICU admission suggested that laboratory-
confirmed co-infection had a significantly higher 30-day mortality
than viral infection alone [hazard ratio (HR) = 1.9, 95% confidence
level (CI): 1.03.5, p = 0.041, N = 98], but not significantly higher than
patients with clinically suspected viral-bacterial co-infection
(HR = 1.4, 95%CI: 0.82.6, p = 0.232, N = 98) or bacterial infection
alone (HR = 1.4, 95%CI: 0.82.5, p = 0.237, N = 97) (Table S6).
In general, the distribution of viruses was: influenza A 10,192
(64.1%), influenza B 1968 (12.4%), parainfluenza 2065 (13.0%) and
RSV 1681 (10.6%). And patients with parainfluenza (8.0%, 95%CI:
6.99.3%) or RSV (8.0%, 95%CI: 6.89.4%) infection had higher 30-day
mortality than those with influenza A (4.7%, 95%CI: 4.35.1%) or
influenza B (4.2%, 95%CI: 3.35.1%). Regarding ICU admission,patients with parainfluenza (5.0%, 95%CI: 4.16.0%) or RSV (3.5%,
95%CI: 2.64.4%) also had higher frequency than those from influ-
enza A (3.3%, 95%CI: 3.03.8%) or influenza B (3.2%, 95%CI: 2.54.1%).
The difference in 30-day mortality and ICU admission amongst differ-
ent viruses remained statistically significant in the viral infection
alone group (p < 0.001). The clinically suspected co-infection group
also showed the significantly difference for 30-day mortality among
different viruses (p < 0.001) but not in the laboratory-confirmed co-
infection group (p = 0.752).
Subgroup analysis on patients without chronic pulmonary disease
or heart failure showed that patients infected with parainfluenza
(8.3%, 95%CI: 6.99.9%) or RSV (8.1%, 95%CI: 6.59.9%) had higher
mortality compared to patients with influenza A (3.8%, 95%CI:
3.44.3%) or influenza B (3.3%, 95%CI: 2.54.3%) (p< 0.001) (Table 3).
3.3. Prevalence and outcomes of different co-infections
The prevalence of specific pathogen combinations in patients with
laboratory-confirmed co-infection and their associated 30-day mor-
tality, ICU admission are shown in Fig. 3. Non-pneumococcal strepto-
cocci species, methicillin-resistant S. aureus (MRSA), and Klebsiella
species were associated with high mortality ranging from 18.9% to
30.0% in influenza infection group (Fig. 3A) and 22.0% to 30.0% for all
viruses (Fig. 3B) but were less common. The prevalence of influenza
A and H. influenza co-infection combination was the highest, but mor-
tality was relatively low (4/123, 3.3% of all cases with laboratory-con-
firmed co-infection) (Fig. 3A). Overall, H. influenzae (226/1087,
20.8%), P. aeruginosa (180/1087,16.6%) and S. pneumoniae (123/1087,
11.3%) were the three most common bacterial pathogens within the
Table 3
Clinical outcomes amongst different viral infection groups.
Influenza A Influenza B Parainfluenza RSV p-value*
30-day mortality
Viral infection alone, N (%, 95 CI%) 181/4042 (4.5, 3.95.2) 31/772 (4.0, 3.06.0) 71/843 (8.4, 6.610.5) 54/711 (7.6, 5.89.8) <0.001
Laboratory-confirmed viral-bacterial co-infec-
tion, N (%, 95 CI%)
64/616 (10.4, 8.113.1) 15/145 (10.3, 6.016.5) 21/185 (11.4, 7.116.8) 19/141 (13.5, 8.320.2) 0.752
Clinically suspected viral-bacterial co-infection,
N (%, 95 CI%)
232/5534 (4.2, 3.74.8) 36/1051 (3.4, 2.44.7) 74/1037 (7.1, 5.68.9) 62/829 (7.5, 5.89.5) <0.001
Total N (%, 95 CI%) 477/10,192 (4.7, 4.35.1) 82/1968 (4.2, 3.35.1) 166/2065 (8.0, 6.99.3) 135/1681 (8.0, 6.89.4) <0.001
ICU admission
Viral infection, N (%, 95 CI%) 129/4042 (3.2, 2.73.8) 21/772 (2.7, 1.74.1) 42/843 (5.0, 3.66.7) 15/711 (2.1, 1.23.5) 0.008
Laboratory-confirmed viral-bacterial co-infec-
tion, N (%, 95 CI%)
50/616 (8.1, 6.110.6) 20/145 (13.8, 8.620.5) 21/185 (11.4, 7.216.8) 12/141 (8.5, 7.216.8) 0.063
Clinically suspected viral-bacterial co-infection,
N (%, 95 CI%)
161/5284 (3.0, 2.63.5) 22/1051 (2.1, 1.33.2) 40/1037 (3.9, 2.85.2) 31/829 (3.7, 2.65.3) 0.145
Total N (%, 95 CI%) 340/10,192 (3.3, 3.03.8) 63/1968 (3.2, 2.54.1) 103/2065 (5.0, 4.16.0) 58/1681 (3.5, 2.64.4) 0.002
Subgroup history of patients without chronic
pulmonary disease or chronic heart failure
Total N (%, 95 CI%) 292/7594 (3.8, 3.44.3) 51/1537 (3.3, 2.54.3) 111/1342 (8.3,6.99.9) 84/1041 (8.1, 6.59.9) <0.001
N: Sample size.
*The p-value refers to the comparisons of the outcomes amongst different viral infection groups using chi-square test.
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contribution of antibiotic resistance to the observed mortality, we
carried out a subgroup analysis of 130 patients with co-infection of
Klebsiella or Escherichia coli (E. coli). Co-infection with these two bac-
terial pathogens accounted for high mortality [Klebsiella: 18/82
(22.0%); E. coli: 8/48 (16.7%)]. Within this subgroup, 17 were positive
for extended spectrum beta-lactamase (ESBL) isolates [Klebsiella: 3/
82 (3.7%); E. coli: 14/48 (13.1%)]. The 30-day mortality was 29.4% (5/
17) in this ESBL-positive subgroup versus in 18.6% (21/113) the ESBL-
negative subgroup (p = 0.42 by chi-square).
4. Discussion
In this retrospective cohort study of 19,361 adult patients hospi-
talized for respiratory infection, 5.6% (1087/19,361) had laboratory-
confirmed viral-bacterial co-infection. The 30-day mortality in these
patients was significantly higher than those with viral infection
alone, bacterial infection alone or clinically suspected co-infection.
Patients with laboratory-confirmed co-infection also had a higher
rate of ICU admission. Within this co-infection group, the most com-
mon bacteria were H. influenzae, P aeruginosa, and S. pneumoniae.
Although H. influenzae type b vaccination was recommended by Cen-
ters for Disease Control and Prevention in the United States, H. influ-
enzae vaccination is not included in the Childhood Immunization
Program in Hong Kong which could be the reason of H. influenzae
having such a high prevalence locally.
The rate of laboratory-confirmed viral-bacterial co-infection in
this cohort of patients was in the lower range of the previously
reported (277%) [31,4045]. This is likely due to heterogeneity of
our study population [46], type of respiratory virus [4749], viral
detection methods [20], case definition, community-acquired or nos-
ocomial co-infection, seasonal variation and pandemics [50,51].
Moreover, we showed that laboratory-confirmed co-infection is asso-
ciated with increased mortality, which is consistent with the findings
from a recent meta-analysis on 31 studies consisting of 10,762
patients with community-acquired pneumonia. Co-infection causes a
more complicated course with increased need for mechanical ventila-
tion and vasopressor therapy, that is reflected in our study by the
higher rates of ICU admission in patients with laboratory-confirmed
viral-bacterial co-infection [10,30,31,5254]. However, subgroup
analysis of ICU patients showed that although the 30-day mortality
of the co-infection group was significantly higher than those with
viral infection alone, there was no difference to bacterial infectionalone group. This may be limited by the small sample size in the bac-
terial infection alone group.
In our cohort, mortality in patients with clinically suspected viral-
bacterial co-infection was similar to those with viral infection alone
and lower than those with laboratory-confirmed co-infection. This
finding challenges the existence of bacterial infection in the majority
of patients with suspected co-infection. In this respect, the neutrophil
count, neutrophil-to-lymphocyte ratio and platelet count in patients
with clinically suspected co-infection were similar to those with viral
infection alone. Clinically, these hematological parameters may be
used to differentiate early bacterial infection or viral-bacterial co-
infection from viral infection alone.
Another notable finding of this study is that H. influenzae (226/
1087, 20.8%), P. aeruginosa (180/1087, 16.8%), and S. pneumoniae
(123/1087, 11.3%) were the three most common bacterial pathogens
in patients with laboratory-confirmed viral-bacterial co-infection.
Given that all co-infection in this cohort was presumably commu-
nity-acquired (samples collected within 48 h of hospital admission),
P. aeruginosa as a more prevalent co-pathogen is surprising. P. aerugi-
nosa had been a rare cause of community-acquired respiratory infec-
tion (0.8%1.9%) [5557]. However, recent studies reported an
increasing rate of P. aeruginosa co-infection with influenza [45]. In
our cohort, among the patients who detected with P. aeruginosa,
15.0% (27/180) and 44.4% (80/180) were diagnosed with congestive
heart failure and chronic pulmonary disease, respectively. In patients
with chronic disease, frequent institutionalized care and recent hos-
pitalization are risk factors for community-acquired P. aeruginosa
infection [58,59]. This may explain the higher prevalence of this path-
ogen in our cohort.
While laboratory-confirmed viral-bacterial co-infection as a non-
specific group had a higher mortality, our results identified specific
bacteria that may be associated with increased mortality. Non-pneu-
mococcal streptococcal species and MRSA, as highly virulent species,
have high mortality [9/30 (30.0%) and 13/48 (27.1%), respectively].
Infections with these pathogens produce anatomical, functional and
immunological changes in the respiratory tract [6,24,6062], and
may predispose and exacerbate subsequent viral or bacterial infec-
tions [63-66]. In addition, co-infection with Klebsiella and E. coli had
high mortality [18/82, (22.0%) and 8/48 (16.7%), respectively]. Impor-
tantly, ESBL positivity was not associated with a significantly higher
mortality, suggesting that the observed high mortality rate in viral-
bacterial co-infection with Klebsiella or E. coli was not mainly due to
antibiotic resistance.
Fig. 3. Prevalence, 30-day mortality and ICU admission of laboratory confirmed viral-bacterial co-infection combinations, 20132017 Crude 30-day mortality and prevalence of dif-
ferent viral-bacterial co-infection combinations were calculated for selected combinations with an incidence  20 cases. The laboratory confirmed viral-bacterial co-infection com-
binations were ordered according to the mortality. The percentage of 30-day mortality and ICU admission refereed to the left y-axis and the prevalence refereed to the right one.
(A) 30-day mortality, ICU admission and prevalence in influenza A co-infection group (N = 538). (B) A total of 1087 bacterial co-infection cases were identified among a total of
15,906 adults hospitalized for respiratory viral infection.
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infection resulted in lower survival rate than influenza. The mortality
difference persisted even in the subgroup of patients without chronic
lung disease and congestive heart failure. However, because influ-
enza, predominantly influenza A, was more common, it caused a
higher number of deaths. Our results are consistent with previous
studies comparing RSV or parainfluenza with influenza [6769].
Unlike the global initiative for influenza prevention with vaccination
among elderly (achieved a coverage of 32.7% to 40.8% in 20132017
in those aged >65 population in Hong Kong) [70]. However there is
currently no effective vaccination for RSV or parainfluenza, which
could cause a higher mortality than influenza in Hong Kong elderly
population.
Our study has several limitations. First, this was a retrospective
study analyzing electronic health records that was prone to bias from
case selection and other processes in the healthcare system. Second,
only the first incidence of single viral/bacterial infection was included
[71,72]. However, we used a population database to capture all adult
hospitalized patients with respiratory viral and bacterial microbio-
logical tests at four major hospitals in Hong Kong over a 5-year
period. This resulted in the largest single cohort to date on co-infec-
tion in community-acquired respiratory infection. Further studies
focusing on multiple bacterial infections or microorganism interac-
tions on metagenomic level are valuable to access the effect of the
co-infection combinations on subsequent respiratory infections.
Third, because we only included patients who had both viral and bac-
terial respiratory tests, this excluded patients who did not or could
not have concurrent viral and bacterial sampling. Fourth, we did not
include adenovirus, enterovirus, rhinovirus, or human metapneumo-
virus because of inconsistent testing during the study period. This
may affect the prevalence of viral-bacterial co-infections. Fifth, unlike
viral PCR which has high sensitivity, our study relied on matrix-
assisted laser desorption/ionization-time of flight mass spectrometry
to identify bacterial pathogens. Furthermore, we were limited by
timestamp resolution of antibiotic administration by date and not
hours. Therefore some patients may have been given antibiotics prior
to bacterial culture which may have reduced yield and biased the
reported bacterial pathogen distribution. Similarly, positive sputum
culture such as S. pneumoniae or S. aureus could be due to asymptom-
atic carriage rather than real infection [73]. Nevertheless both of
these factors would have reduced rather than exaggerated the mor-
tality difference in patients with co-infection. Another disadvantage
of studying co-infection using bacterial culture against viral PCR is
the inability to capture pathogens which cannot be cultured. Future
research using metagenomics and metatranscriptomics may be use-
ful to develop a complete blueprint of viral-bacterial co-infection of
the respiratory tract. Sixth, we were unable to assess the appropriate-
ness of antibiotic therapy according to bacterial sensitivity. However
clinicians were trained to adjust antibiotic therapy according to sen-
sitivity, therefore the lack of this assessment should not affect the
findings in this study. Furthermore, the rates of resistant organisms
(MRSA and ESBL) were low in this cohort (160/4542, 3.5%), therefore
this limitation is unlikely to cast major impact in this cohort.
Viral-bacterial co-infection is not uncommon (6.8%) among adult
patients hospitalized for respiratory viral infection and is associated
with higher mortality and increased need for ICU admission. The
most common co-infected bacteria were H. influenzae, P aeruginosa,
and S. pneumoniae. Co-infection with non- pneumococcal streptococ-
cal species and MRSA are associated with high mortality.5. Funding
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